Prescription drug · ANDA
Fosaprepitant NDC 68001-421
Fosaprepitant dimeglumine 150 mg/5mL · Injection, Powder, Lyophilized, For solution · Intravenous · BluePoint Laboratories
NDC codes
FDA NDC DirectoryProduct information
- Brand name (proprietary)
- Fosaprepitant
- Generic name (nonproprietary)
- fosaprepitant
- Active ingredients
- Fosaprepitant dimeglumine — 150 mg/5mL
- Dosage form
- Injection, Powder, Lyophilized, For solution
- Route
- Intravenous
- Labeler
- BluePoint LaboratoriesNDC labeler code 68001
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 205020
- Marketing start
- Listing expires
- Other FDA classes
- Cytochrome P450 2C9 Inducers (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)Neurokinin 1 Antagonists (Mechanism)
- Identifiers
- Product ID 68001-421_0f37486e-8181-f7cf-e063-6394a90a9af1SPL ID 0f37486e-8181-f7cf-e063-6394a90a9af1SPL set ID 46edae30-d50c-4112-9941-954b13ed5edaRxCUI 1731077UNII D35FM8T64X
- Pharmacologic class
- Substance P/Neurokinin-1 Receptor Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use Fosaprepitant for injection has not been studied for the treatment of established nausea and vomiting. Pediatric use information is approved for Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.’s Emend (fosaprepitant) for injection. However, due to Merck Sharp & Dohm…
Excerpt only. Read the full label for complete information.
About NDC 68001-421
- What is NDC 68001-421?
- 68001-421 is the product NDC for Fosaprepitant, Fosaprepitant dimeglumine 150 mg/5mL injection, powder, lyophilized, for solution, listed with the FDA by BluePoint Laboratories.
- What drug is associated with this NDC?
- Fosaprepitant.
- What is the active ingredient?
- Fosaprepitant dimeglumine.
- Who is the labeler?
- BluePoint Laboratories, NDC labeler code 68001. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Fosaprepitant?
- 18 other product NDCs are listed under this name. See all Fosaprepitant NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Fosaprepitant products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Fosaprepitant | Fosaprepitant dimeglumine 150 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous | Dr. Reddy's Laboratories Inc., | 43598-671 | 43598-0671-11 |
| Fosaprepitant | Fosaprepitant dimeglumine 150 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | BluePoint Laboratories | 68001-675 | 68001-0675-25 |
| Fosaprepitantfosaprepitant dimeglumine | Fosaprepitant dimeglumine 150 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | Avenacy, LLC | 83634-776 | 83634-0776-10 |
| Fosaprepitantfosaprepitant dimeglumine | Fosaprepitant dimeglumine 150 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | NorthStar RxLLC | 16714-248 | 16714-0248-01 |
| Fosaprepitantfosaprepitant dimeglumine | Fosaprepitant dimeglumine 150 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | BluePoint Laboratories | 68001-523 | 68001-0523-36 |
| Fosaprepitantfosaprepitant dimeglumine | Fosaprepitant dimeglumine 150 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | Camber Pharmaceuticals, Inc. | 31722-165 | 31722-0165-31 |
| Fosaprepitantfosaprepitant dimeglumine | Fosaprepitant dimeglumine 150 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 71731-5111 | 71731-5111-01 |
| Fosaprepitant | Fosaprepitant dimeglumine 150 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | Dr. Reddy's Laboratories Inc., | 43598-948 | 43598-0948-11 |
| Fosaprepitant | Fosaprepitant dimeglumine 150 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | Bryant Ranch Prepack | 72162-2636 | 72162-2636-02 |
| Fosaprepitant | Fosaprepitant dimeglumine 150 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | Novadoz Pharmaceuticals LLC | 72205-054 | 72205-0054-01 |